Search alternatives:
small decrease » small increased (Expand Search)
Showing 821 - 840 results of 2,520 for search '(( aromatic decrease ) OR ( ((small decrease) OR (dramatic decrease)) ))', query time: 0.38s Refine Results
  1. 821

    Table 5_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.docx by Tien Le (634791)

    Published 2025
    “…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
  2. 822

    Image 4_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff by Tien Le (634791)

    Published 2025
    “…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
  3. 823

    Image 9_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff by Tien Le (634791)

    Published 2025
    “…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
  4. 824

    Image 5_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff by Tien Le (634791)

    Published 2025
    “…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
  5. 825

    Table 2_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.docx by Tien Le (634791)

    Published 2025
    “…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
  6. 826

    Data Sheet 1_The flavonoid of Dracocephalum heterophyllum Benth. ameliorates cerebral small vessel disease by inhibiting the autophagy via Angs-Tie2 signaling pathway.docx by Lin Liu (74495)

    Published 2025
    “…Background<p>Cerebral small vessel disease (CSVD) is a common cause of stroke and vascular cognitive impairment. …”
  7. 827

    Effect of Molecular Structure on the B3LYP-Computed HOMO–LUMO Gap: A Structure −Property Relationship Using Atomic Signatures by Ahmed Mohamed (628889)

    Published 2025
    “…The atomic fragments containing π-bonds in various aromatic compounds were found to be the most significant atomic Signatures, explaining nearly 50% of the variance in the data, with regression coefficients that decreased <i>E</i><sub>gap</sub>. …”
  8. 828
  9. 829

    Table 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.docx by Nafeisha Simayi (22262161)

    Published 2025
    “…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
  10. 830

    Data Sheet 2_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.pdf... by Nafeisha Simayi (22262161)

    Published 2025
    “…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
  11. 831

    Data Sheet 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.zip... by Nafeisha Simayi (22262161)

    Published 2025
    “…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
  12. 832
  13. 833
  14. 834
  15. 835
  16. 836
  17. 837
  18. 838
  19. 839
  20. 840